o morzu BEZ CENZURY! - opinie internautów

[offshore10]

Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating lung disease with a median survival of just 3-5 years from diagnosis. There are currently no approved treatments for IPF, and the only FDA-approved medication is Ofev (nintedanib), which was shown to slow the rate of decline in lung function by about 50% compared to placebo in a clinical trial.

There are several other medications that are commonly used to treat the symptoms of IPF, such as shortness of breath and cough, and to help prevent further decline in lung function. These include pirfenidone, a medication that was shown to slow the rate of decline in lung function by about 54% compared to placebo in a clinical trial, and Esbriet, a medication that was shown to improve exercise capacity and quality of life in patients with IPF in a clinical trial.

In addition to these medications, there are a number of other treatments that may be helpful in managing the symptoms of IPF and slowing the progression of the disease. These include supplemental oxygen, pulmonary rehabilitation, and lung transplantation.